Literature DB >> 21598625

[In vitro and in vivo efficacy of Ingavirin against strains of pandemic influenza virus A(H1N1/09)v].

L N Shishkina, V E Nebol'sin, A S Kabanov, M O Skarnovich, N A Mazurkova, A A Sergeev, O A Serova, E A Stavskiĭ, I G Drozdov.   

Abstract

AIM: To study efficacy of Ingavirin in vitro and in vivo against strains of pandemic influenza virus A(H1N1/09)v and influenza virus A(H5N1) and A(H3N2).
MATERIALS AND METHODS: Changes in hemagglutinating and cytopathic activity of influenza virus strains A(H1N1/09)v, A(H5N1) and A(H3N2) during their incubation in the presence of Ingavirin or Remantadin on MDCK cell culture were studied. In mice infected by influenza strains A(H1N1/09)v and A(H3N2) and orally treated with Ingavirin, Tamiflu or Remantadin virus titers in lungs were measured.
RESULTS: There was decrease in hemagglutinating and cytopathic activity of influenza virus strains after incubation with Ingavirin in vitro. Ingavirin effectively inhibited reproduction of influenza virus strains A(H1N1/09)v and A(H3N2) in lungs of infected mice. Titers of these strains in lung homogenates decreased when Ingavirin was orally administered to infected mice.
CONCLUSION: Strains of influenza virus A(H1N1/09)v were susceptible to Ingavirin and Tamiflu but resistant to Remantadin. Reference strains of A(H5N1) and A(H3N2) were susceptible to Ingavirin, Tamiflu and Remantadin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21598625

Source DB:  PubMed          Journal:  Zh Mikrobiol Epidemiol Immunobiol        ISSN: 0372-9311


  3 in total

1.  Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo.

Authors:  Peter Fedichev; Roman Timakhov; Tim Pyrkov; Evgeny Getmantsev; Andrey Vinnik
Journal:  PLoS Curr       Date:  2011-08-07

2.  Activity of Ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxo-hexanoic Acid) Against Human Respiratory Viruses in in Vivo Experiments.

Authors:  Vladimir V Zarubaev; Angelica V Garshinina; Nelly A Kalinina; Anna A Shtro; Svetlana V Belyaevskaya; Alexander V Slita; Vladimir E Nebolsin; Oleg I Kiselev
Journal:  Pharmaceuticals (Basel)       Date:  2011-11-25

Review 3.  Progress of small molecular inhibitors in the development of anti-influenza virus agents.

Authors:  Xiaoai Wu; Xiuli Wu; Qizheng Sun; Chunhui Zhang; Shengyong Yang; Lin Li; Zhiyun Jia
Journal:  Theranostics       Date:  2017-02-08       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.